Cancer BiologybioRxiv
ARPP19 promotes MYC expression and associates with patient relapse in acute myeloid leukemia
E. Makela, E. Loyttyniemi, U. Salmenniemi…·J. Westermarck
This study identifies ARPP19 as an oncogenic PP2A inhibitor in AML that predicts relapse independently of risk classification and is associated with disease activity.
DOI 10.3390/cancers11111774